-
Intensive insulin therapy in the ICU is a dynamic and controversial issue that has played out in the medical literature, at the bedside, and in the offices of policy makers over the last 8 years.
-
This study was designed to determine whether intensive glucose control in ICU patients reduces mortality at 90 days. Secondary outcomes included survival time during the 90 days, cause-specific death, duration of mechanical ventilation, need for renal replacement therapy, and hospital and ICU lengths of stay.
-
The ICU is commonly viewed as a stressful environment. While common, stress responses are likely to vary over time, between individuals, and as a result of the context in which they occur.
-
Colonization of the respiratory tract and other sites with Candida species is common in ICU patients but it is unclear how often these species cause pneumonia that warrants antifungal therapy.
-
Along with yearly vaccination, the U.S. Centers for Disease Control and Prevention (CDC) recommend the use of personal protective equipment (PPE) by health care workers (HCWs) to prevent influenza infection in the ICU.
-
The need for participation of the primary care physician in the treatment of sleep apnea has become much more apparent in recent years.
-
-
Aspirin dose and cardioprotection; uncovering modafinil's abuse potential; proton-pump inhibitors and clopidogrel; FDA actions.
-
-
Since the risk of gastrointestinal bleeding is increased when clopidogrel is added to aspirin therapy in patients with acute coronary syndromes (ACS), many prescribe proton-pump inhibitors (PPIs) to reduce this risk. However, mechanistic studies suggest that PPIs may reduce the effectiveness of clopidogrel.